Trials / Recruiting
RecruitingNCT05145517
A Post-Market Clinical Follow-up Study in Patients Treated With Vascular Grafts
FLOWGRAFT - A Post-Market Clinical Follow-up Study in Patients Treated With Vascular Grafts
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- JOTEC GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The FLOWGRAFT post-market clinical follow-up study is undertaken to show the safety and performance of FlowWeave Bioseal, FlowNit Bioseal, FlowLine Bipore and FlowLine Bipore Heparin (combined named as Vascular Grafts) in the treatment of arterial diseases, such as dissection, aneurysm, intramural hematoma (IMH), penetrating aortic ulcer (PAU), contained rupture, stenosis in the aorta or peripheral arteries (lower limbs). This includes the use of FlowWeave Bioseal or FlowNit Bioseal for debranching of the head vessels in an alone standing procedure. Furthermore, it includes the use of the FlowLine Bipore and FlowLine Bipore Heparin Grafts as arterious-venous (AV) shunt.
Detailed description
In this study, patients who receive a Vascular Graft for the treatment of arterial diseases (aneurysm, PAU, IMH, dissection, stenosis) of the aorta or peripheral arteries (lower limbs) or as an AV shunt will be observed. This includes patients in whom the Vascular Grafts are used for debranching or reconstruction of the head vessels. Participating physicians will be asked to provide the observations, that were collected during routine care. Written informed consent, specifically allowing the use of clinical records for this observational study, will be obtained from every patient prior to data collection. The period of data collection will be approximately 60 + 6 months (depending on the date of the last follow-up visit) from the date of intervention for each patient.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Open repair | Open repair of the aorta and peripheral arteries |
Timeline
- Start date
- 2021-12-06
- Primary completion
- 2024-10-01
- Completion
- 2030-03-30
- First posted
- 2021-12-06
- Last updated
- 2022-05-19
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05145517. Inclusion in this directory is not an endorsement.